Myriad Genetics Inc. (MYGN) share price drops due to weak fundamental momentum – Marketing Sentinel



Myriad Genetics Inc. (NASDAQ: MYGN) has a beta value of 1.61 and saw 0.47 million shares traded in the last trading session. The company, currently valued at $ 2.41 billion, closed the last trade at $ 31.30 per share, meaning it lost – $ 0.01 on the day or – 0.03% over the course of the day. of this session. The MYGN share price is -8.53% from its 52-week high of $ 33.97 and 64.7% above the 52-week low of $ 11.05. The volume of transactions over 3 months is 537.50K shares.

>> 7 top choices for the post-pandemic economy

The consensus among analysts is that Myriad Genetics Inc. (MYGN) is currently an underweight stock, with a recommendation rating of 3.20. 4 analysts rate the stock as a sell, while 0 rates it as an overweight. 5 out of 10 rated it as an expectation, with 1 recommending it as a buy. 0 rated the stock as underweight.

With -0.03% in the red in the last session, the stock has traded in the red over the past five days, with the highest price being reached on Friday 07/02/21 when the price MYGN stock rose to $ 31.30 or was up 4.57. %. Year-to-date shares of Myriad Genetics Inc. have moved 58.28%, while the 5-day performance has seen it move -4.02%. Over the past 30 days, shares of Myriad Genetics Inc. (NASDAQ: MYGN) have changed 14.90%.

Wall Street analysts have a consensus price target for the stock at $ 27.75, which means the stock’s value could fall -12.79% from current levels. The projected low price target is $ 15.00 while the price target sits at a high of $ 37.00. In this case, then, we find that the current price level is -18.21% from the high target while a dip would see the stock lose 52.08% from current levels.

Myriad Genetics Inc. (MYGN) Estimates and Forecasts

The company’s shares have gained 58.28% in the past 6 months, compared to 8.40% for the industry.

If we assess the growth of the company over the past 5 years and for the following 5-year period, we find that the annual profit growth was -21.20% over the past 5 years. Profit growth for 2021 is a modest 63.40% while over the next 5 years the company’s profits are expected to decline by -8.20%.

>> 7 top choices for the post-pandemic economy

MYGN dividends

Myriad Genetics Inc. is expected to release its next earnings report in August of this year, and investors are excited about the prospect of better dividends despite the company’s debt problem.

5 stocks under $ 10 that are about to take off

Investing in stocks under $ 10 could dramatically increase your portfolio returns, especially if you pick the right stocks! In this report, you will find the top 5 stocks that offer investors huge upside potential and the best value for money.

Add them to your watchlist before they take off!

Get the 5 best stocks now!



Leave A Reply

Your email address will not be published.